Alphatec Q4 EPS of $0.06 vs Loss Year Ago, Revenue Up 20.5% to $212.9 M
Alphatec posted Q4 adjusted EPS of $0.06, 50% above the $0.04 consensus and up from a $0.23 loss a year earlier, while revenue climbed 20.5% to $212.9 million, beating estimates by 0.1%. Shares have slid 37.5% year-to-date despite four straight quarters of revenue outperformance, raising valuation concerns.
1. Q4 Financial Results
Alphatec delivered adjusted earnings of $0.06 per share in Q4, surpassing the $0.04 estimate and reversing a $0.23-per-share loss from Q4 2024. Revenue rose 20.5% year-over-year to $212.93 million, topping forecasts by 0.13%.
2. Consistent Estimate Outperformance
The company has beaten consensus EPS estimates in three of the past four quarters and revenue targets in each of the last four, underlining steady execution in its medical instruments segment. Historical surprises include a 200% EPS beat in the prior quarter, reinforcing management’s focus on margin improvement.
3. Stock Price Reaction
Despite operational wins, Alphatec shares have declined roughly 37.5% since January 1, significantly underperforming the broader market’s flat return. The steep sell-off suggests investor concern over valuation and sustainability of current growth before the next earnings update.
4. Forward Outlook and Analyst Estimates
Current consensus projects Q1 EPS of $0.01 on revenue of $201.3 million and full-year EPS of $0.24 on $889.3 million in revenue. Market watchers will monitor estimate revisions and management commentary for signals on maintaining these growth trends.